Tuesday, March 8, 2011

XDx heart transplant test wins 'medically necessary' tag from Aetna

Molecular diagnostics company XDx Inc. won an important victory as national insurance provider Aetna Inc. determined that the Brisbane company’s heart transplant test is “medically necessary” more than one year after a transplant.
Aetna’s (NYSE: AET) decision would likely help validate the AlloMap test further, and that has an impact on cash flow and the bottom line. Notably, 89-employee XDx often has to appeal each test when insurers initially say they won’t pay for it. Sometimes that goes all the way to an administrative judge.

No comments:

Post a Comment